Novartis Says FDA Approves Expanded Use For Leqvio
(RTTNews) - Novartis AG (NVS) announced Monday that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.
This patient population includes those who have comorbidities such as hypertension and diabetes and have not yet had a first cardiovascular event.
Initially approved by the FDA in December 2021, Leqvio is the first and only small interfering RNA (siRNA) therapy to lower LDL-C.
The updated indication for primary hyperlipidemia allows for the expanded use of Leqvio as an adjunct to diet and statin therapy beyond the previously approved atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) patient populations.
Effective immediately in the US, this label update reinforces the robust safety and effectiveness data for Leqvio that are being generated by the VictORION clinical trial program.
VictORION is one of the largest cardiovascular clinical trial programs with more than 20 trials and is designed for consistent and comprehensive data generation.
Novartis Lifts FY24 Outlook After Q3 Beats Market; But Stock Down
Novartis Reports Positive Results From Phase III ASC4FIRST Trial; Meets Both Primary Endpoints
Novartis Q1 Profit Tops Market, Lifts FY24 View, Proposes New Chair; Stock Up
Novartis Stock Down As Q4 Core EPS Miss Estimates; Sees Growth In FY24
Novartis Recalls Sandimmune Oral Solution
Novartis Recalls One Lot Of Sandimmune Oral Solution 100 Mg/mL
Novartis Lifts FY23 View As Q2 Results Top Market, Initiates $15 Bln Buyback; Stock Up
